论文部分内容阅读
目的:观察冠心病心绞痛患者介入治疗后炎症因子和内皮功能变化及通心络的干预作用,并探讨其临床意义。方法:60例入选患者接受PCI术后分为常规治疗组和常规治疗加通心络组,采用超声多普勒测量治疗前后肱动脉内皮舒张功能,并测定其CRP、ICAM-1、IL-10等炎症因子。结果:通心络组和对照组与健康人的血清各炎症因子比较,均有显著差异(P<0.01)。常规治疗组ICAM-1、CRP经治疗后下降,IL-10升高(P<0.05)。与对照组比较,通心络组以上3种炎症因子改变更为显著(P<0.01和P<0.05)。通心络组治疗后FMD明显改善,且较对照组差异显著(P均<0.01),而NMD则只在通心络组中治疗后有改善,比对照组变化显著(P<0.05)。结论:冠心病患者血清炎症因子明显高于健康对照者,通心络可在常规治疗基础上更显著降低其炎症反应,且改善血管内皮功能。
OBJECTIVE: To observe the changes of inflammatory factors and endothelial function after interventional therapy in patients with coronary heart disease and the intervention of Tongxinluo, and to explore its clinical significance. Methods: Sixty patients selected for PCI were divided into routine treatment group and routine treatment plus Tongxinluo group. The diastolic function of brachial artery before and after treatment was measured by Doppler ultrasound. The levels of CRP, ICAM-1 and IL-10 Other inflammatory factors. Results: There were significant differences in serum inflammatory factors between Tongxinluo group and control group and healthy people (P <0.01). ICAM-1 and CRP in the conventional treatment group decreased after treatment and IL-10 increased (P <0.05). Compared with the control group, the changes of the above three inflammatory factors in Tongxinluo group were more significant (P <0.01 and P <0.05). Compared with the control group, the FMD of Tongxinluo group was significantly improved (P <0.01), while that of NMD group was only improved after treatment in Tongxinluo group (P <0.05). Conclusion: Serum inflammatory cytokines in patients with coronary heart disease were significantly higher than those in healthy controls. Tongxinluo significantly reduced the inflammatory response and improved endothelial function in patients with coronary heart disease.